New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Imaging Agents markets. Global market for Imaging Agents is projected to reach US$15.7 billion by 2020, driven by innovations in imaging technologies, rise in diagnostic examinations, growing geriatric population and rising use of advanced SPECT/CT and PET/CT scanners.

Imaging Agents: A Global Strategic Business Report

Follow us on LinkedIn – Imaging agents, an integral part of the medical imaging market, are engineered to enhance the anatomic visualization of human organs. Effervescent technology developments over the past three decades have expanded the application roles of imaging agents in medical diagnostics. From barium and iodine based agents used for over half a century to newer variants such as gold nanoparticles and radiopharmaceuticals, imaging agents have witnessed sea changes, revolutionizing in the process the field of medical diagnosis. Growth in the market is primarily driven by rise in imaging procedure volumes against the backdrop of an aging world population and increasing incidence of chronic diseases. Also contributing to the growth is expansion of imaging modalities in new clinical applications and advancements such as whole body screening, therapeutic monitoring, and image guided therapeutic interventions. Development of targeted agents is expected to further accelerate market growth.

Contrast media constitutes the largest segment with future growth in this market forecast to come from strong demand for image guided surgical procedures, technological advancements in diagnostic imaging and growing incidence of diseases such as cancer and cardiac failure. Within the contrast media segment, the mature X-ray contrast media technology is being overshadowed by contemporary modalities such as MRI and Ultrasound, which are engineered to specially target specific tissues, such as, the liver and lymph nodes. Advancements in molecular diagnostics is also expected to drive the development of new contrast agents capable of detecting metabolic changes at the molecular level and assess functional changes associated with heart, cancer, and neurological diseases. Fluorescence optical imaging, an evolving medical imaging modality, offers the potential to complement existing molecular imaging techniques. Development of advanced imaging agents is expected to facilitate high precision diagnostics as well as promote the practice of personalized medicine in the most cost-effective manner.

Diagnostic radiopharmaceuticals are poised to register the fastest growth over the analysis period, buoyed by rising usage of Single Photon Emission Computed Tomography- Computer Tomography (SPECT-CT). Radiopharmaceuticals hold the potential to offer better disease management to the elderly suffering from cognitive conditions by providing early disease identification and reduced cost of healthcare.

As stated by the new market research report on Imaging Agents, the United States represents the largest market worldwide. Asia-Pacific is forecast to witness the fastest growth, trailing a CAGR of 10.3% over the analysis period, driven by increasing number of imaging procedures and penetration of imaging technologies. Growing awareness over the importance of early diagnosis of diseases for improved management constitutes another major factor driving demand for medical imaging equipment and imaging agents.

Major players covered in the report include Bayer Healthcare Pharmaceuticals, Bracco Diagnostics Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, GE Healthcare, Guerbet Group, Lantheus Medical Imaging Inc., and Mallinckrodt Pharmaceuticals among others.

The research report titled “Imaging Agents: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for all major geographic markets including the United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, India and Rest of Asia-Pacific), Middle East and Latin America (Brazil and Rest of Latin America). Product segments analyzed include Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals.

For more details about this comprehensive market research report, please visit –

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site:


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website